×

FcγRIIB specific antibodies and methods of use thereof

  • US 8,968,730 B2
  • Filed: 07/03/2008
  • Issued: 03/03/2015
  • Est. Priority Date: 08/14/2002
  • Status: Active Grant
First Claim
Patent Images

1. A method of enhancing immune response to an antigen in a patient by blocking negative regulation of immune-complex-triggered activation, wherein said antigen is associated with a cancer or a neoplastic disease or is an antigen of a pathogen, said method comprising administering to said patient:

  • (i) an antigen-antibody complex; and

    (ii) an antibody or an antigen-binding fragment thereof that specifically binds the extracellular domain of human Fcγ

    RIIB with greater affinity than human Fcγ

    RIIA and inhibits binding to the Fc binding site of human Fcγ

    RIIB, wherein said antibody or antigen-binding fragment thereof comprises the six CDRs of antibody produced by clone 2B6 having ATCC Accession No. PTA-4591 or the six CDRs of antibody produced by clone 3H7 having ATCC Accession No. PTA-4592;

    to thereby enhance immune response in said patient to said antigen.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×